KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Accumulated Expenses (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Accumulated Expenses for 8 consecutive years, with $83.0 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 15.74% to $83.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $83.0 million through Dec 2025, down 15.74% year-over-year, with the annual reading at $83.0 million for FY2025, 15.74% down from the prior year.
  • Accumulated Expenses hit $83.0 million in Q4 2025 for Vir Biotechnology, up from $68.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $489.1 million in Q4 2022 to a low of $3.1 million in Q1 2023.
  • Historically, Accumulated Expenses has averaged $122.2 million across 5 years, with a median of $82.8 million in 2025.
  • Biggest five-year swings in Accumulated Expenses: crashed 89.01% in 2022 and later soared 2225.72% in 2024.
  • Year by year, Accumulated Expenses stood at $236.5 million in 2021, then surged by 106.79% to $489.1 million in 2022, then plummeted by 78.69% to $104.2 million in 2023, then decreased by 5.47% to $98.5 million in 2024, then decreased by 15.74% to $83.0 million in 2025.
  • Business Quant data shows Accumulated Expenses for VIR at $83.0 million in Q4 2025, $68.4 million in Q3 2025, and $82.7 million in Q2 2025.